3 Takeaways From ADA

Why It Matters

These regulatory and clinical milestones broaden access to closed‑loop insulin therapy, positioning Tandem and Insulet for growth in the fast‑expanding European market while Dexcom’s CGM data could shift standard care for non‑insulin Type 2 patients worldwide.

Key Takeaways

• Tandem’s t:slim X2 pump gains EU CE mark for pregnant Type 1 users
• Tandem’s devices show 12.6% more time-in-range for pregnant participants
• Insulet’s Omnipod 6 achieves 77% time-in-range, surpassing Omnipod 5
• Insulet’s upcoming AID aims to eliminate mealtime boluses for Type 2
• Dexcom G7 sensors cut A1C by 1.6% in non‑insulin Type 2 patients

Pulse Analysis

The European CE mark awarded to Tandem’s t:slim X2 and Mobi pumps marks the first time a major U.S. AID manufacturer has secured continent‑wide clearance for both Type 2 diabetes and pregnant Type 1 patients. By meeting the EU’s stringent medical‑device standards, Tandem can now market its closed‑loop solution across 27 member states, unlocking a market worth an estimated €1.2 billion (≈ $1.3 billion). This regulatory win not only validates the safety of its Control‑IQ+ algorithm but also pressures rivals to accelerate their own label extensions.

The underlying clinical evidence is equally compelling. The Circuit trial, published in JAMA, demonstrated a 12.6 % boost in time‑in‑range for pregnant users, a demographic historically excluded from automated insulin delivery. Meanwhile, a New England Journal of Medicine study of more than 300 Type 2 participants showed significantly larger A1C reductions compared with standard insulin regimens. Insulet’s Omnipod 6, which posted 77 % time‑in‑range, and its experimental AID that removes mealtime boluses, further illustrate how manufacturers are leveraging trial data to differentiate product pipelines.

Dexcom’s G7 results add another layer to the evolving diabetes‑care landscape. A 1.6 % A1C drop and five extra hours per day in target range for non‑insulin‑using Type 2 patients provide Level A evidence that continuous glucose monitoring can improve outcomes beyond insulin‑dependent cohorts. As payers and clinicians recognize these benefits, CGM adoption is likely to accelerate, creating cross‑selling opportunities for pump makers and reinforcing the shift toward fully integrated, data‑driven diabetes management.